Fepixnebart

Fepixnebart (LY3016859) is a humanized monoclonal hIgG4 antibody, which binds and neutralizes only TGFα and epiregulin with high affinity. Fepixnebart can be used for the study of diabetic nephropathy and broad-spectrum chronic pain, including diabetic peripheral neuropathic pain (DPNP), signs and symptoms of osteoarthritis (OA), and chronic low back pain (CLBP) [1][2].

Product Specifications

CAS Number

[2489584-93-0]

Product Name Alternative

LY-3016859

UNSPSC

12352203

Target

EGFR

Type

Inhibitory Antibodies

Related Pathways

JAK/STAT Signaling; Protein Tyrosine Kinase/RTK

Applications

Cancer-programmed cell death

Field of Research

Metabolic Disease; Inflammation/Immunology; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/fepixnebart.html

Purity

96.40

Solubility

10 mM in DMSO

Smiles

[Fepixnebart]

Molecular Weight

(145.44 kDa)

References & Citations

[1]Boyles JS, et al. Structural basis of selectivity and neutralizing activity of a TGFα/epiregulin specific antibody. Protein Sci. 2016 Nov;25 (11) :2028-2036. |[2]James DE, et al. Population Pharmacokinetics and Pharmacodynamics of Fepixnebart (LY3016859) and Epiregulin in Patients with Chronic Pain. Clin Pharmacokinet. 2025 May;64 (5) :757-767.